| scholarly article | Q13442814 |
| P356 | DOI | 10.1185/030079903125002469 |
| P698 | PubMed publication ID | 14687444 |
| P2093 | author name string | D Feldman | |
| D Scott | |||
| D Uebelhart | |||
| I W Rodger | |||
| R Gerli | |||
| J Zacher | |||
| Z E Ozturk | |||
| S-M Hou | |||
| etoricoxib OA study group | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| patient | Q181600 | ||
| Diclofenac | Q244408 | ||
| P304 | page(s) | 725-736 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Current Medical Research and Opinion | Q5195063 |
| P1476 | title | A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis | |
| P478 | volume | 19 |
| Q24615651 | A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity |
| Q60907501 | Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac |
| Q46437932 | Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q34570225 | Clinical pharmacology of etoricoxib |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q38262502 | Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs |
| Q36486905 | Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs |
| Q37900856 | Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale |
| Q24634894 | Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review |
| Q39320502 | Efficacy and safety of etoricoxib in the treatment of osteoarthritis |
| Q38993297 | Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses |
| Q41963113 | Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison |
| Q46937537 | Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q47756560 | Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q41850972 | Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation |
| Q37257464 | Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials |
| Q36013803 | Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials |
| Q33214797 | Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients |
| Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
Search more.